Invesco Pharmaceuticals ETF
$129.63−0.91 (−0.69%)
- 0.58%
- $582M
- +36.1%
- 0.87%
- 39.2K sh
- low $95.92high $131.88
The ETF.net PJP Grade
B
Score 63 out of 100
- 5 of 9
Score 63 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.C41 out of 100Rank 5 of 9Mission
Whether the fund did what it promised, tested against its stated mandate.A80 out of 100Rank 1 of 6Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.A70 out of 100Rank 3 of 9Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.B62 out of 100Rank 4 of 9Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.A80 out of 100Rank 2 of 9Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.B64 out of 100Rank 5 of 9
Our read on PJP
In short
BMost pharma ETFs simply own the sector's biggest names. PJP runs a rules-based screen for momentum, quality and value across US drugmakers and holds only the roughly 30 that clear it, for 0.58% a year.
Stated mandate
The fund seeks capital appreciation by investing primarily in pharmaceutical companies selected through the Dynamic Pharmaceutical Intellidex Index.
Why people hold it
Worth knowing
PJP Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
PJP$13,607
Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | PJP |
|---|---|
| Year to date | +25.9% |
| 1 month | +5.9% |
| 3 months | +7.7% |
| 1 year | +36.1% |
| 3 years | +25.0% |
| 5 years | +11.7% |
| 10 years | +9.8% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | PJP |
|---|---|---|
| 2026 YTD | +25.9% | |
| 2025 | +28.0% | |
| 2024 | +9.6% | |
| 2023 | −2.2% | |
| 2022 | −2.2% | |
| 2021 | +14.6% | |
| 2020 | +11.3% |
PJP in the news
PJP Dividends
- 0.87%
- $1.13
- $0.30 per share
- Quarterly
PJP Risk
- 14.1%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 1.34
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −17.5%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.44
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
FMP measures it over up to five years of monthly returns.
PJP Cost
Overpaying vs PBPH, cheapest in Pharma & Therapeutics
$8,727
On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.
PJP 0.58%
$11,453
PBPH 0.13% Cheapest
$2,726
Cost over time
Year by year
| Year | PJP | PBPH | Overpaying |
|---|---|---|---|
| 10 | $1,041 | $238 | $803 |
| 20 | $3,986 | $930 | $3,056 |
| 30 | $11,453 | $2,726 | $8,727 |
Other funds in Pharma & Therapeutics
- BIHEiShares U.S. Pharmaceuticals ETFExpense ratio 0.37%1 year return +43.9%
- BPBPHPortfolio Building Block World Pharma and Biotech Index ETFExpense ratio 0.13%1 year return
- BFTXHFirst Trust Nasdaq Pharmaceuticals ETFExpense ratio 0.60%1 year return +47.8%
- CTHNRAmplify Weight Loss Drug & Treatment ETFExpense ratio 0.59%1 year return +13.2%
- COZEMRoundhill GLP-1 & Weight Loss ETFExpense ratio 0.59%1 year return +8.1%
